DALBAVANCIN IS NOT A SUBSTRATE, INHIBITOR, OR INDUCER OF CYP450 ISOENZYMES. DALBAVANCIN PHARMACOKINETICS WERE NOT AFFECTED BY CO-ADMINISTRATION WITH KNOWN CYP450 SUBSTRATES, INDUCERS OR INHIBITORS, NOR BY INDIVIDUAL MEDICATIONS INCLUDING ACETAMINOPHEN, AZTREONAM, FENTANYL, METRONIDAZOLE, FUROSEMIDE, PROTON PUMP INHIBITORS (OMEPRAZOLE, ESOMEPRAZOLE, PANTOPRAZOLE, LANSOPRAZOLE), MIDAZOLAM, AND SIMVASTATIN.